Windlas Biotech Limited has scheduled a series of meetings with analysts and institutional investors between July 2 and July 7, 2026, to discuss its performance and strategy. The company will engage with entities including Vara Capital, Apricus Wealth Investment Managers, Trust Mutual Fund, Baring Private Equity Partners India, and Vaikarya Investment Management during these sessions. These interactions are part of the company's ongoing investor relations efforts under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Windlas Biotech stated that discussions will rely solely on publicly available documents. The company explicitly confirmed that no unpublished price sensitive information (UPSI) will be shared during these interactions. Ananta Narayan Panda, Company Secretary & Compliance Officer, signed the intimation on June 24, 2026.

Meeting Schedule

The company noted that changes to the schedule may occur due to exigencies on the part of investors, analysts, or the company.

Windlas Biotech Limited reported a 19% year-on-year increase in revenue to ₹904 crores for the financial year ended March 31, 2026, driven by strong performance across its verticals. The company achieved its highest post-listing EPS of ₹31.60 and maintained ROCE and ROE above the 25% mark. For the quarter ended March 31, 2026, revenue grew 18% year-on-year to ₹238 crores, marking the 13th consecutive quarter of record revenue.

Financial Performance

The company’s adjusted EBITDA for FY26 stood at ₹121 crores, representing a margin of 13.4%, while Profit After Tax (PAT) was ₹83 crores, or 9.2%. In Q4 FY26, adjusted EBITDA reached ₹33 crores with a margin of 13.6%, and PAT was ₹23 crores. On a reported basis, EBITDA grew 11% to ₹105 crores and PAT rose 9% to ₹66 crores for the full year. The business generated ₹105 crores of net operating cash flows, closing the year with a net liquidity position of ₹251 crores.

Segment Performance

The Generic Formulations CDMO vertical achieved revenues of ₹664 crores in FY26 and ₹176 crores in Q4 FY26, reflecting 20% year-on-year growth. The Trade Generics and Institutional vertical grew 13% to ₹195 crores in FY26, while the export vertical saw a significant 40% growth to ₹46 crores in FY26, with Q4 revenue increasing 67% year-on-year to ₹17 crores.

Strategic Developments

During the year, Plant 4 and Plant 5, the injectable facility, received GMP certification from the Philippines. Plant 6 achieved mechanical completion and remains on track for commercialization by H1 of FY27. The Board has proposed a dividend of ₹13 crores, or ₹6.3 per share, for FY26. The management emphasized its focus on capital efficiency, operational discipline, and expanding its client base to drive long-term value.